|
depression |
17 |
|
anxiety |
13 |
|
covid-19 |
12 |
|
network analysis |
12 |
|
coping strategies |
7 |
|
correlates |
7 |
|
loneliness |
7 |
|
mental disorders |
7 |
|
post-traumatic stress disorder |
7 |
|
pre-existing mental disorders |
7 |
|
psychiatric patients |
7 |
|
psychopathology |
7 |
|
social support |
7 |
|
suicidal ideation |
7 |
|
survey |
7 |
|
coping styles |
6 |
|
self-reported cognitive complaints |
6 |
|
traumatic stress symptoms |
6 |
|
cardiovascular disease |
5 |
|
genetics |
5 |
|
mendelian randomization |
5 |
|
screening |
5 |
|
meta-analysis |
4 |
|
methamphetamine |
4 |
|
pulmonary hypertension |
4 |
|
antipsychotic agents - adverse effects - pharmacology - therapeutic use |
2 |
|
aripiprazole |
2 |
|
bazett's correction |
2 |
|
cannabis |
2 |
|
clozapine |
2 |
|
cognitive function |
2 |
|
consensus statement |
2 |
|
databases, factual |
2 |
|
hong kong |
2 |
|
long qt syndrome - chemically induced |
2 |
|
pharmacy and pharmacology |
2 |
|
qt interval |
2 |
|
risk |
2 |
|
schizophrenia |
2 |
|
schizophrenia - drug therapy |
2 |
|
second-generation antipsychotics |
2 |
|
treatment resistant schizophrenia |
2 |
|
addiction |
1 |
|
atypical antipsychotic drug |
1 |
|
bipolar |
1 |
|
bipolar disorder |
1 |
|
cannabis use disorder |
1 |
|
chinese sds |
1 |
|
comorbidity |
1 |
|
consensus statements |
1 |
|
dopamine |
1 |
|
fab |
1 |
|
genotype |
1 |
|
guidance |
1 |
|
ketamine |
1 |
|
long-acting injectable antipsychotics |
1 |
|
longitudinal study |
1 |
|
maintenance |
1 |
|
moca |
1 |
|
psychometrics |
1 |
|
psychosis |
1 |
|
risperidone |
1 |
|
risperidone long-acting injection |
1 |
|
stimulant use |
1 |
|
substance use disorder |
1 |
|
tardive dyskinesia |
1 |
|
vortioxetine |
1 |
